Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267163 · ClinicalTrials.gov registry record · Phase 4
Brain Imaging and Mental Disorders of Aging Intervention
A Phase 4 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00267163 is a Phase 4 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 64 participants.
The verdict
NCT00267163, a Phase 4 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2000-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267163
The ClinicalTrials.gov registry entry for NCT00267163 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00267163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267163 about?
NCT00267163 is a clinical study titled "Brain Imaging and Mental Disorders of Aging Intervention". The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.
What is the current status of trial NCT00267163?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2000-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00267163?
The interventions under investigation include: Placebo (DRUG), donepezil (DRUG).
Who is sponsoring clinical trial NCT00267163?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.